Automated Suturing Devices Market by Product Type (Disposable Devices, Reusable Devices), Technology (Electrosurgical, Mechanical), Suture Material, Automation Level, Application, End User - Global Forecast 2025-2032
Description
The Automated Suturing Devices Market was valued at USD 910.67 million in 2024 and is projected to grow to USD 991.00 million in 2025, with a CAGR of 8.97%, reaching USD 1,811.07 million by 2032.
A comprehensive landscape introduction explaining how automation, clinical needs, and regulatory momentum are redefining suturing practices and procurement
Automated suturing devices are reshaping surgical practice by integrating precision engineering, automation, and tissue-specific design principles into routine procedures. The technology landscape spans electrosurgical and mechanical platforms designed to reduce operative time, enhance suture consistency, and support minimally invasive approaches. Clinical adoption is driven by a combination of device ergonomics, procedural efficacy, and the growing emphasis on standardizing outcomes across surgical teams. As hospitals and specialty centers prioritize efficiency and patient safety, automated suturing solutions are increasingly considered essential components of modern operating suites.
Moreover, regulatory developments and advances in device interoperability with existing surgical systems have encouraged investment from device manufacturers and healthcare providers alike. Cross-disciplinary collaboration between clinicians, biomedical engineers, and health system administrators has accelerated iterative improvements in device usability and performance. Consequently, stakeholders are redirecting procurement criteria to include total cost of ownership, training pathways for surgical staff, and post-market surveillance data. Taken together, these factors are propelling automated suturing from a niche adjunct to a core element of contemporary surgical toolkits.
Key technological, procedural, and regulatory inflection points that are accelerating adoption and altering competitive strategies in the suturing device market
Several transformative shifts are converging to alter the competitive and clinical landscape for automated suturing devices. First, miniaturization and sensor integration have improved device feedback and control, enabling more precise handling of delicate tissues and widening the scope of viable applications. Second, the growing emphasis on minimally invasive and laparoscopic approaches has increased demand for devices that can deliver reproducible results through small access ports, thereby reducing recovery times and complication rates. Third, the convergence of machine-assisted mechanisms and advanced suture materials is driving innovations in both disposable and reusable device architectures, changing how hospitals think about lifecycle costs and sterilization protocols.
In parallel, reimbursement environments and value-based care initiatives are pressuring manufacturers to demonstrate demonstrable clinical benefits, such as reductions in operative time, lower complication rates, and improved patient throughput. This, in turn, is prompting more rigorous clinical evaluations and partnerships with key opinion leaders. Finally, supply chain resilience and regional regulatory navigation are becoming competitive differentiators as companies expand beyond traditional markets. Collectively, these shifts are catalyzing a faster-than-expected maturation of the automated suturing segment and reshaping strategic priorities across manufacturers, providers, and procurement organizations.
How 2025 tariff revisions are reshaping sourcing choices, pricing dynamics, and procurement preparedness across the automated suturing supply chain
Tariff changes enacted in 2025 have introduced new variables into supply chain strategies and commercial planning for medical device companies, with particular implications for imported components and finished goods. Manufacturers that rely on cross-border sourcing for high-precision components have faced higher landed costs, prompting an evaluation of nearshoring, supplier consolidation, and vertical integration. In response, some organizations have initiated redesign efforts to substitute tariff-exposed parts with domestically available alternatives or to reconfigure assembly flows to minimize tariff exposure.
These adjustments have significant downstream effects on pricing negotiations, distributor agreements, and hospital procurement cycles. Health systems that operate under fixed reimbursement schedules or tight capital planning windows have had to re-evaluate timing for capital purchases and elective upgrades. Simultaneously, suppliers with integrated regional manufacturing capabilities gained relative pricing flexibility, enabling them to advance competitive bids for large system-level contracts. While tariffs have not altered the clinical imperatives driving adoption, they have reshaped commercial dynamics, supplier selection criteria, and contingency planning for both incumbent and emerging device companies.
In-depth segmentation insights connecting clinical applications, end-user environments, product typologies, technology variants, suture substrates, and automation tiers
Segment-specific insights reveal nuanced demand drivers tied to clinical application, care setting, product architecture, technology modality, suture substrate, and automation level. Based on Application, the market is studied across Cardiovascular Surgery, Colorectal Surgery, General Surgery, Gynecological Surgery, and Orthopedic Surgery, each presenting distinct tissue handling requirements, regulatory pathways, and clinical outcome priorities that influence device form factor and performance specifications. Transitioning between specialties, devices often require adaptation in needle geometry, energy delivery, or staple compression to meet clinical safety margins.
Based on End User, the market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics, which vary in case mix complexity, capital budgeting cycles, and training bandwidth for new devices. Procurement preferences reflect these operational differences, with ambulatory centers emphasizing throughput and cost-per-case metrics while tertiary hospitals prioritize versatility and integration with advanced surgical platforms. Based on Product Type, the market is studied across Disposable Devices and Reusable Devices, with each model creating trade-offs between per-procedure cost, sterilization logistics, and inventory management. Based on Technology, the market is studied across Electrosurgical and Mechanical. The Electrosurgical is further studied across Bipolar and Ultrasonic. The Mechanical is further studied across Compression Clip and Stapling Mechanism, and these technological distinctions drive divergent clinical protocols and maintenance needs. Based on Suture Material, the market is studied across Absorbable and Non-absorbable, affecting long-term tissue response and follow-up care strategies. Based on Automation Level, the market is studied across Fully Automatic and Semi-automatic, which influence operator training requirements, procedure timing, and risk mitigation strategies.
Regional adoption profiles and strategic considerations highlighting divergent regulatory, reimbursement, and procurement dynamics across major global territories
Regional dynamics reflect heterogeneous adoption curves, regulatory frameworks, and payer environments across major global markets. In the Americas, strong hospital networks and a focus on minimally invasive surgical expansion have fostered demand for devices that reduce operative time and standardize outcomes, while procurement cycles are influenced by centralized group purchasing organizations and complex reimbursement models. Regulatory pathways emphasize post-market reporting and clinical evidence, leading vendors to invest in region-specific clinical studies and KOL engagement to support adoption.
Across Europe, Middle East & Africa, diverse regulatory regimes and variable hospital infrastructure create a patchwork of opportunity. Western European markets typically prioritize interoperability and long-term service contracts, whereas emerging markets in the region present high-growth potential for cost-effective disposable technologies and simplified training programs. In the Asia-Pacific region, rapid hospital expansion, a growing middle-class patient base, and increasing investment in high-acuity care are driving demand for advanced suturing solutions. Manufacturers looking to scale in this region often focus on localized partnerships, regulatory harmonization strategies, and adaptable pricing models to account for differing procurement capabilities and clinical needs.
Strategic competitive overview emphasizing clinical evidence generation, supply chain resilience, and commercialization models that drive differentiation and market traction
Competitive dynamics in the automated suturing device space are characterized by a mix of established medical device firms and focused innovators, with competition centered on clinical validation, device ergonomics, and service ecosystems. Leading manufacturers emphasize multidisciplinary clinical trials and real-world evidence generation to substantiate claims related to reduced operative time and improved tissue apposition. At the same time, specialized entrants concentrate on specific niches such as single-use instruments or technology platforms optimized for minimally invasive access.
Strategically, companies are investing in partnerships with health systems to co-design training curricula and post-market surveillance frameworks, thereby lowering barriers to adoption and improving clinician confidence. Supply chain resilience has become another differentiator, with vertically integrated firms or those that have diversified manufacturing footprints achieving greater pricing stability in the face of tariff fluctuations. Product roadmaps increasingly incorporate digital enablement features-such as usage telemetry and maintenance scheduling-to create recurring revenue streams and strengthen customer lock-in. Altogether, the competitive environment rewards organizations that can combine clinical credibility, operational reliability, and responsive commercialization models.
Actionable strategic recommendations for market leaders to accelerate adoption, reduce supply chain vulnerabilities, and build durable commercial advantage
Industry leaders should prioritize a set of pragmatic actions that balance near-term commercial responsiveness with longer-term product and operational resilience. First, invest in robust clinical validation programs that align with payer and hospital demands for demonstrable outcomes, using comparative studies to highlight procedural efficiencies and patient-centric benefits. Second, accelerate supply chain diversification and regional manufacturing options to mitigate tariff and logistics risk, while exploring component standardization to reduce supplier dependency. Third, design tiered product portfolios that address distinct end-user needs, offering both cost-efficient disposable options for high-volume ambulatory settings and durable platforms for tertiary hospitals.
In addition, leaders should embed training and service offerings into commercial contracts to lower adoption friction and to capture lifecycle service revenue. Digital enablement-such as device usage data and preventative maintenance alerts-should be integrated thoughtfully to support clinical decision-making and to create measurable value for buyers. Finally, cultivate partnerships with key opinion leaders and health system innovators to co-develop workflows and to accelerate guidelines incorporation. Implementing these measures will strengthen market positioning while ensuring adaptability to regulatory and reimbursement shifts.
Transparent and rigorous research approach blending clinical interviews, regulatory review, and scenario modeling to validate insights and strategic implications
The research methodology underpinning this executive summary combined qualitative and quantitative analytical techniques to ensure a comprehensive understanding of the automated suturing landscape. Primary inputs included structured interviews with practicing surgeons, procurement officers, and device engineers, complemented by site visits to clinical facilities to observe device utilization and workflow impacts. Secondary research incorporated regulatory filings, clinical trial registries, and peer-reviewed literature to corroborate performance claims and to contextualize safety considerations.
Analytical approaches involved technology segmentation mapping, care-pathway analysis, and scenario-based supply chain modeling to evaluate the effects of tariff changes and regional regulatory variance. Stakeholder validation sessions were conducted to test hypotheses and refine strategic implications. Wherever possible, triangulation of multiple sources was used to enhance the validity of insights and to minimize single-source bias. Ethical considerations and confidentiality agreements were observed throughout primary engagement, and interpretations were framed to support actionable decision-making without disclosing proprietary or patient-level data.
Concluding synthesis highlighting how clinical utility, technological refinement, and strategic resilience will determine long-term leadership in automated suturing
Automated suturing devices are at an inflection point where clinical need, technological capability, and commercial strategy intersect to create meaningful opportunities for improved surgical outcomes. While adoption trajectories vary by application and region, the overarching trend is toward devices that deliver reproducible tissue handling, improve procedural efficiency, and align with value-based care objectives. Strategic resilience-built through diversified supply chains, focused clinical validation, and service-oriented commercialization-will separate market leaders from laggards.
Moving forward, successful organizations will be those that translate technical innovation into tangible, measurable benefits for clinicians and health systems. By prioritizing interoperability, training, and evidence generation, manufacturers can reduce adoption barriers and accelerate integration into standard surgical practice. In sum, the automated suturing segment presents a compelling case for focused investment and disciplined execution to capture the clinical and commercial upside that lies ahead.
Note: PDF & Excel + Online Access - 1 Year
A comprehensive landscape introduction explaining how automation, clinical needs, and regulatory momentum are redefining suturing practices and procurement
Automated suturing devices are reshaping surgical practice by integrating precision engineering, automation, and tissue-specific design principles into routine procedures. The technology landscape spans electrosurgical and mechanical platforms designed to reduce operative time, enhance suture consistency, and support minimally invasive approaches. Clinical adoption is driven by a combination of device ergonomics, procedural efficacy, and the growing emphasis on standardizing outcomes across surgical teams. As hospitals and specialty centers prioritize efficiency and patient safety, automated suturing solutions are increasingly considered essential components of modern operating suites.
Moreover, regulatory developments and advances in device interoperability with existing surgical systems have encouraged investment from device manufacturers and healthcare providers alike. Cross-disciplinary collaboration between clinicians, biomedical engineers, and health system administrators has accelerated iterative improvements in device usability and performance. Consequently, stakeholders are redirecting procurement criteria to include total cost of ownership, training pathways for surgical staff, and post-market surveillance data. Taken together, these factors are propelling automated suturing from a niche adjunct to a core element of contemporary surgical toolkits.
Key technological, procedural, and regulatory inflection points that are accelerating adoption and altering competitive strategies in the suturing device market
Several transformative shifts are converging to alter the competitive and clinical landscape for automated suturing devices. First, miniaturization and sensor integration have improved device feedback and control, enabling more precise handling of delicate tissues and widening the scope of viable applications. Second, the growing emphasis on minimally invasive and laparoscopic approaches has increased demand for devices that can deliver reproducible results through small access ports, thereby reducing recovery times and complication rates. Third, the convergence of machine-assisted mechanisms and advanced suture materials is driving innovations in both disposable and reusable device architectures, changing how hospitals think about lifecycle costs and sterilization protocols.
In parallel, reimbursement environments and value-based care initiatives are pressuring manufacturers to demonstrate demonstrable clinical benefits, such as reductions in operative time, lower complication rates, and improved patient throughput. This, in turn, is prompting more rigorous clinical evaluations and partnerships with key opinion leaders. Finally, supply chain resilience and regional regulatory navigation are becoming competitive differentiators as companies expand beyond traditional markets. Collectively, these shifts are catalyzing a faster-than-expected maturation of the automated suturing segment and reshaping strategic priorities across manufacturers, providers, and procurement organizations.
How 2025 tariff revisions are reshaping sourcing choices, pricing dynamics, and procurement preparedness across the automated suturing supply chain
Tariff changes enacted in 2025 have introduced new variables into supply chain strategies and commercial planning for medical device companies, with particular implications for imported components and finished goods. Manufacturers that rely on cross-border sourcing for high-precision components have faced higher landed costs, prompting an evaluation of nearshoring, supplier consolidation, and vertical integration. In response, some organizations have initiated redesign efforts to substitute tariff-exposed parts with domestically available alternatives or to reconfigure assembly flows to minimize tariff exposure.
These adjustments have significant downstream effects on pricing negotiations, distributor agreements, and hospital procurement cycles. Health systems that operate under fixed reimbursement schedules or tight capital planning windows have had to re-evaluate timing for capital purchases and elective upgrades. Simultaneously, suppliers with integrated regional manufacturing capabilities gained relative pricing flexibility, enabling them to advance competitive bids for large system-level contracts. While tariffs have not altered the clinical imperatives driving adoption, they have reshaped commercial dynamics, supplier selection criteria, and contingency planning for both incumbent and emerging device companies.
In-depth segmentation insights connecting clinical applications, end-user environments, product typologies, technology variants, suture substrates, and automation tiers
Segment-specific insights reveal nuanced demand drivers tied to clinical application, care setting, product architecture, technology modality, suture substrate, and automation level. Based on Application, the market is studied across Cardiovascular Surgery, Colorectal Surgery, General Surgery, Gynecological Surgery, and Orthopedic Surgery, each presenting distinct tissue handling requirements, regulatory pathways, and clinical outcome priorities that influence device form factor and performance specifications. Transitioning between specialties, devices often require adaptation in needle geometry, energy delivery, or staple compression to meet clinical safety margins.
Based on End User, the market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics, which vary in case mix complexity, capital budgeting cycles, and training bandwidth for new devices. Procurement preferences reflect these operational differences, with ambulatory centers emphasizing throughput and cost-per-case metrics while tertiary hospitals prioritize versatility and integration with advanced surgical platforms. Based on Product Type, the market is studied across Disposable Devices and Reusable Devices, with each model creating trade-offs between per-procedure cost, sterilization logistics, and inventory management. Based on Technology, the market is studied across Electrosurgical and Mechanical. The Electrosurgical is further studied across Bipolar and Ultrasonic. The Mechanical is further studied across Compression Clip and Stapling Mechanism, and these technological distinctions drive divergent clinical protocols and maintenance needs. Based on Suture Material, the market is studied across Absorbable and Non-absorbable, affecting long-term tissue response and follow-up care strategies. Based on Automation Level, the market is studied across Fully Automatic and Semi-automatic, which influence operator training requirements, procedure timing, and risk mitigation strategies.
Regional adoption profiles and strategic considerations highlighting divergent regulatory, reimbursement, and procurement dynamics across major global territories
Regional dynamics reflect heterogeneous adoption curves, regulatory frameworks, and payer environments across major global markets. In the Americas, strong hospital networks and a focus on minimally invasive surgical expansion have fostered demand for devices that reduce operative time and standardize outcomes, while procurement cycles are influenced by centralized group purchasing organizations and complex reimbursement models. Regulatory pathways emphasize post-market reporting and clinical evidence, leading vendors to invest in region-specific clinical studies and KOL engagement to support adoption.
Across Europe, Middle East & Africa, diverse regulatory regimes and variable hospital infrastructure create a patchwork of opportunity. Western European markets typically prioritize interoperability and long-term service contracts, whereas emerging markets in the region present high-growth potential for cost-effective disposable technologies and simplified training programs. In the Asia-Pacific region, rapid hospital expansion, a growing middle-class patient base, and increasing investment in high-acuity care are driving demand for advanced suturing solutions. Manufacturers looking to scale in this region often focus on localized partnerships, regulatory harmonization strategies, and adaptable pricing models to account for differing procurement capabilities and clinical needs.
Strategic competitive overview emphasizing clinical evidence generation, supply chain resilience, and commercialization models that drive differentiation and market traction
Competitive dynamics in the automated suturing device space are characterized by a mix of established medical device firms and focused innovators, with competition centered on clinical validation, device ergonomics, and service ecosystems. Leading manufacturers emphasize multidisciplinary clinical trials and real-world evidence generation to substantiate claims related to reduced operative time and improved tissue apposition. At the same time, specialized entrants concentrate on specific niches such as single-use instruments or technology platforms optimized for minimally invasive access.
Strategically, companies are investing in partnerships with health systems to co-design training curricula and post-market surveillance frameworks, thereby lowering barriers to adoption and improving clinician confidence. Supply chain resilience has become another differentiator, with vertically integrated firms or those that have diversified manufacturing footprints achieving greater pricing stability in the face of tariff fluctuations. Product roadmaps increasingly incorporate digital enablement features-such as usage telemetry and maintenance scheduling-to create recurring revenue streams and strengthen customer lock-in. Altogether, the competitive environment rewards organizations that can combine clinical credibility, operational reliability, and responsive commercialization models.
Actionable strategic recommendations for market leaders to accelerate adoption, reduce supply chain vulnerabilities, and build durable commercial advantage
Industry leaders should prioritize a set of pragmatic actions that balance near-term commercial responsiveness with longer-term product and operational resilience. First, invest in robust clinical validation programs that align with payer and hospital demands for demonstrable outcomes, using comparative studies to highlight procedural efficiencies and patient-centric benefits. Second, accelerate supply chain diversification and regional manufacturing options to mitigate tariff and logistics risk, while exploring component standardization to reduce supplier dependency. Third, design tiered product portfolios that address distinct end-user needs, offering both cost-efficient disposable options for high-volume ambulatory settings and durable platforms for tertiary hospitals.
In addition, leaders should embed training and service offerings into commercial contracts to lower adoption friction and to capture lifecycle service revenue. Digital enablement-such as device usage data and preventative maintenance alerts-should be integrated thoughtfully to support clinical decision-making and to create measurable value for buyers. Finally, cultivate partnerships with key opinion leaders and health system innovators to co-develop workflows and to accelerate guidelines incorporation. Implementing these measures will strengthen market positioning while ensuring adaptability to regulatory and reimbursement shifts.
Transparent and rigorous research approach blending clinical interviews, regulatory review, and scenario modeling to validate insights and strategic implications
The research methodology underpinning this executive summary combined qualitative and quantitative analytical techniques to ensure a comprehensive understanding of the automated suturing landscape. Primary inputs included structured interviews with practicing surgeons, procurement officers, and device engineers, complemented by site visits to clinical facilities to observe device utilization and workflow impacts. Secondary research incorporated regulatory filings, clinical trial registries, and peer-reviewed literature to corroborate performance claims and to contextualize safety considerations.
Analytical approaches involved technology segmentation mapping, care-pathway analysis, and scenario-based supply chain modeling to evaluate the effects of tariff changes and regional regulatory variance. Stakeholder validation sessions were conducted to test hypotheses and refine strategic implications. Wherever possible, triangulation of multiple sources was used to enhance the validity of insights and to minimize single-source bias. Ethical considerations and confidentiality agreements were observed throughout primary engagement, and interpretations were framed to support actionable decision-making without disclosing proprietary or patient-level data.
Concluding synthesis highlighting how clinical utility, technological refinement, and strategic resilience will determine long-term leadership in automated suturing
Automated suturing devices are at an inflection point where clinical need, technological capability, and commercial strategy intersect to create meaningful opportunities for improved surgical outcomes. While adoption trajectories vary by application and region, the overarching trend is toward devices that deliver reproducible tissue handling, improve procedural efficiency, and align with value-based care objectives. Strategic resilience-built through diversified supply chains, focused clinical validation, and service-oriented commercialization-will separate market leaders from laggards.
Moving forward, successful organizations will be those that translate technical innovation into tangible, measurable benefits for clinicians and health systems. By prioritizing interoperability, training, and evidence generation, manufacturers can reduce adoption barriers and accelerate integration into standard surgical practice. In sum, the automated suturing segment presents a compelling case for focused investment and disciplined execution to capture the clinical and commercial upside that lies ahead.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
180 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of artificial intelligence algorithms for real-time suturing guidance and error reduction
- 5.2. Advancements in robotic-assisted suturing systems enabling minimally invasive complex procedures
- 5.3. Development of disposable single-use suturing cartridges to reduce cross-contamination risks
- 5.4. Integration of haptic feedback technology for improved surgeon tactile perception during automated suturing
- 5.5. Adoption of wireless data connectivity in automated suturing devices for performance analytics and remote monitoring
- 5.6. Regulatory approvals for single-port automated suturing devices expanding applications in outpatient surgery centers
- 5.7. Collaborations between medical device manufacturers and AI software firms accelerating innovation in suturing automation
- 5.8. Cost reduction strategies through modular device design and standardized suturing cartridges for faster market adoption
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Automated Suturing Devices Market, by Product Type
- 8.1. Disposable Devices
- 8.2. Reusable Devices
- 9. Automated Suturing Devices Market, by Technology
- 9.1. Electrosurgical
- 9.1.1. Bipolar
- 9.1.2. Ultrasonic
- 9.2. Mechanical
- 9.2.1. Compression Clip
- 9.2.2. Stapling Mechanism
- 10. Automated Suturing Devices Market, by Suture Material
- 10.1. Absorbable
- 10.2. Non-absorbable
- 11. Automated Suturing Devices Market, by Automation Level
- 11.1. Fully Automatic
- 11.2. Semi-automatic
- 12. Automated Suturing Devices Market, by Application
- 12.1. Cardiovascular Surgery
- 12.2. Colorectal Surgery
- 12.3. General Surgery
- 12.4. Gynecological Surgery
- 12.5. Orthopedic Surgery
- 13. Automated Suturing Devices Market, by End User
- 13.1. Ambulatory Surgical Centers
- 13.2. Hospitals
- 13.3. Specialty Clinics
- 14. Automated Suturing Devices Market, by Region
- 14.1. Americas
- 14.1.1. North America
- 14.1.2. Latin America
- 14.2. Europe, Middle East & Africa
- 14.2.1. Europe
- 14.2.2. Middle East
- 14.2.3. Africa
- 14.3. Asia-Pacific
- 15. Automated Suturing Devices Market, by Group
- 15.1. ASEAN
- 15.2. GCC
- 15.3. European Union
- 15.4. BRICS
- 15.5. G7
- 15.6. NATO
- 16. Automated Suturing Devices Market, by Country
- 16.1. United States
- 16.2. Canada
- 16.3. Mexico
- 16.4. Brazil
- 16.5. United Kingdom
- 16.6. Germany
- 16.7. France
- 16.8. Russia
- 16.9. Italy
- 16.10. Spain
- 16.11. China
- 16.12. India
- 16.13. Japan
- 16.14. Australia
- 16.15. South Korea
- 17. Competitive Landscape
- 17.1. Market Share Analysis, 2024
- 17.2. FPNV Positioning Matrix, 2024
- 17.3. Competitive Analysis
- 17.3.1. 3M Company
- 17.3.2. B. Braun Melsungen AG
- 17.3.3. Baxter International Inc.
- 17.3.4. ConMed Corporation
- 17.3.5. DemeTECH Corporation
- 17.3.6. Ethicon, Inc.
- 17.3.7. Intuitive Surgical, Inc.
- 17.3.8. Karl Storz SE & Co. KG
- 17.3.9. Medtronic plc
- 17.3.10. Mellon Medical B.V.
- 17.3.11. Olympus Corporation
- 17.3.12. Péters Surgical, Inc.
- 17.3.13. Smith & Nephew plc
- 17.3.14. Surgical Innovations Ltd
- 17.3.15. Sutrue Limited
- 17.3.16. TELA Bio, Inc.
- 17.3.17. Teleflex Incorporated
- 17.3.18. Teleflex, Inc.
- 17.3.19. Zimmer Biomet Holdings, Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
